Lift of Stay Disallowed by District Court Post-SAS in View of PTAB’s Final Written Decision Lacking Non-Instituted Claims

Jun 18, 2018

Reading Time : 2 min

On July 29, 2015, DermaFocus LLC—a non-practicing entity—filed suit against Ulthera, Inc. in the District of Delaware alleging that the Ulthera infringed U.S. Patent No. 6,113,559 (the “’559 patent”) relating to a method and apparatus for therapeutic treatment of skin with ultrasound. Just shy of one year after DermaFocus’s complaint (on July 19, 2016), Ulthera filed an IPR challenging all claims of the ’559 patent. On November 11, 2016 the parties agreed to stay the district court litigation until the PTAB denied institution or issued a final written decision. Ultimately, the PTAB instituted IPRs on 16 of 18 claims and, on January 19, 2018, issued a final written decision rejecting all of Ulthera’s validity challenges. Consequently, DermaFocus moved to lift the stay.

Courts typically consider three factors when determining whether to stay, or lift a stay, in district court: (1) whether the stay will simplify the issues for trial; (2) the status of the litigation; and (3) whether the nonmoving party will be prejudiced—based on timing, delay, and the relationship of the parties. DermaFocus’s arguments to lift the stay centered on the more than two-year delay in litigation and the fact that the stay’s purpose had been fulfilled following the PTAB’s final written decision finding that all 16 instituted claims were patentable. Ulthera opposed the motion to lift the stay and instead sought a continuation based on its appeal to the Federal Circuit.

Although the aforementioned three factors normally govern motions to stay, Magistrate Judge Fallon determined that the SAS Institute decision mandated a different outcome. In SAS Institute, the Supreme Court ruled against the PTAB’s practice of partial institutions and held that the PTAB must issue final written decisions “with respect to patentability of any patent claim challenged” and that, in this context, “‘any’ means ‘every.’”

In the parallel IPR proceeding, the PTAB had instituted IPR on only 16 of the patent’s 18 claims. Accordingly, following the Supreme Court’s decision, Ulthera had filed a motion with the Federal Circuit requesting remand of the appeal to the PTAB for issuance of a final decision regarding patentability of the two claims not instituted. The Federal Circuit granted Ulthera’s remand motion and stated that the PTAB had “to resolve the patentability of all challenged claims in the pending IPR proceeding.”

As such, Magistrate Judge Fallon ruled that the parties’ stay agreement had not been fulfilled—specifically, the stipulation that the stay would be lifted “pending resolution by the PTAB of the patentability of all challenged claims in the pending IPR.” The motion to lift the stay was, therefore, denied because the conditions for originally implementing the stay still existed:  the PTAB had not finished considering all challenged claims in light of the SAS Institute decision.

DermaFocus LLC v. Ulthera, Inc., 1-15-cv-00654 (D. Del. June 7, 2018) (Fallon, MJ) (order denying motion to lift stay)

Share This Insight

Previous Entries

IP Newsflash

August 11, 2025

In considering a motion to dismiss infringement claims for two related patents, the District of Massachusetts recently held that pre-suit knowledge of a “parent” patent, without more, is insufficient to establish pre-suit knowledge of the “child” patent for purposes of indirect and willful infringement.

...

Read More

IP Newsflash

August 8, 2025

Following a jury verdict finding trade secret misappropriation, the District Court for the District of Massachusetts granted-in-part a plaintiff’s motion for a permanent injunction to prohibit defendants from using plaintiff’s trade secrets. The district court further required defendants to reassign to plaintiff patents and patent applications that disclosed or were derived from plaintiff’s trade secrets as part of its equitable relief.

...

Read More

IP Newsflash

August 6, 2025

In ruling on a recent motion to strike, a judge in the Eastern District of Texas permitted a damages expert to rely on a damages theory based on defendant’s “avoided costs,” holding that this theory did not run afoul of the “entire market value rule.”

...

Read More

IP Newsflash

August 5, 2025

The Federal Circuit recently vacated a decision by the Patent Trial and Appeal Board after concluding that the board’s analysis of licensing evidence offered as a secondary consideration of nonobviousness constituted legal error and was not supported by substantial evidence. According to the court, the board applied a more exacting and improperly heightened nexus standard than is required by law for license evidence.

...

Read More

IP Newsflash

August 5, 2025

A Northern District of California judge recently granted a motion to reconsider his summary judgment ruling that defendant was barred from raising certain “device art” due to IPR estoppel under 35 U.S.C. § 315(e)(2). In the original ruling, the judge adopted the broader rule that IPR estoppel applies to device art that is “materially identical” to patents or printed publications that petitioners raised, or could have raised, in an IPR. Following that ruling, however, the Federal Circuit issued its Ingenico decision adopting the narrower view that IPR estoppel applies only to “grounds” based on patents and printed publications and not to device-based grounds. Citing Ingenico as a “change of law,” defendant moved for reconsideration of the court’s ruling, and the court granted the motion.

...

Read More

IP Newsflash

August 5, 2025

In a recent decision designated as Informative, the USPTO Director determined that the Patent Trial and Appeal Board abused its discretion by instituting two inter partes review proceedings challenging the same patent, based on petitions advancing different constructions of the same claim term. The Director expressed concerns that permitting multiple petitions based on alternative claim constructions effectively circumvents word count limitations, strains board resources, and undermines procedural efficiency.

...

Read More

IP Newsflash

July 25, 2025

Earlier this year, the Federal Circuit’s decision in Qualcomm Inc. v. Apple Inc. (Qualcomm II) raised questions about the extent to which petitioners can rely on applicant admitted prior art (“AAPA”) in inter partes review proceedings.  The Federal Circuit’s recent decision in Shockwave Medical, Inc. v. Cardiovascular Sys., Inc. largely cabins the Qualcomm II decision to its particular facts and makes clear that AAPA can be used as evidence of background knowledge as part of an obviousness argument.

...

Read More

IP Newsflash

July 11, 2025

The Federal Circuit recently reversed a PTAB determination on remand that a patent was obvious over applicant admitted prior art (“AAPA”) in combination with prior art patents, holding that expressly designating AAPA as a “basis” for a ground is improper under 35 U.S.C. § 311(b). In doing so, the Court rejected the PTAB’s “blanket rule” that “AAPA used in combination with prior art patents or printed publications under § 311(b) is ipso facto not the basis or part of the basis of a ground.” Ultimately, while the case clarifies that expressly listing AAPA in an IPR ground is improper, the precise line between proper and improper uses of AAPA in other instances remains unclear.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.